Liquidia (LQDA) – Investment Analysts’ Weekly Ratings Changes

Liquidia (NASDAQ: LQDA) recently received a number of ratings updates from brokerages and research firms:

• 6/5/2026 – Liquidia had its price target raised by HC Wainwright from $67.00 to $75.00. They now have a “buy” rating on the stock.
• 6/5/2026 – Liquidia was given a new $75.00 price target by Oppenheimer Holdings, Inc..
• 6/5/2026 – Liquidia was given a new $28.00 price target by HC Wainwright.
• 6/4/2026 – Liquidia had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $68.00 price target on the stock.
• 5/16/2026 – Liquidia was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/12/2026 – Liquidia had its price target raised by HC Wainwright from $55.00 to $67.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Liquidia had its price target raised by Wells Fargo & Company from $51.00 to $62.00. They now have an “overweight” rating on the stock.
• 5/11/2026 – Liquidia had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $60.00 price target on the stock.
• 5/11/2026 – Liquidia had its price target raised by Needham & Company LLC from $54.00 to $70.00. They now have a “buy” rating on the stock.
• 5/11/2026 – Liquidia had its price target raised by BTIG Research from $50.00 to $59.00. They now have a “buy” rating on the stock.
• 5/5/2026 – Liquidia was upgraded by Zacks Research from “hold” to “strong-buy”.
• 4/21/2026 – Liquidia had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Insiders Place Their Bets

In related news, Director Stephen M. Bloch sold 72,534 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $64.38, for a total value of $4,669,738.92. Following the completion of the sale, the director directly owned 1,564,407 shares of the company’s stock, valued at $100,716,522.66. The trade was a 4.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Arthur S. Kirsch sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was sold at an average price of $54.80, for a total value of $548,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,673,680 shares of company stock worth $85,949,087 over the last three months. Insiders own 25.60% of the company’s stock.

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).